Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis
Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.
BY Jason R. Gotlib
PUBLISHED March 22, 2016
Jason R. Gotlib, associate professor of Medicine (Hematology) at Stanford University Medical Center, discusses JAK inhibitors for the treatment of patients with myelofibrosis.
Gotlib discusses whether next-generation JAK inhibitors should be used after resistance to Jakafi (ruxolitinib) or in the frontline setting. Gotlib also provided an overview of drugs that are being studied in combination with these agents.
Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.